Insiders

Pfizer Chief Scientific Officer Mikael Dolsten Leaving

July 09, 2024 at 04:45 pm IST

By Colin Kellaher

Pfizer on Tuesday said Mikael Dolsten, chief scientific officer and president, Pfizer Research & Development, is leaving after more than 15 years with the drugmaker.

Pfizer said it is launching the process to identify a successor, which it said will likely run through early next year.

The New York company said it plans an external search for a new chief scientific officer, adding that Dolsten will assist in the search and will remain in his post until his successor is in place.

Dolsten joined Pfizer as part of its blockbuster acquisition of Wyeth in 2009.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

07-09-24 0715ET

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	PFIZER, INC.	30.03 USD	+1.80%	+5.93%	17TCr

Mikael Dolsten

Mikael Dolsten holds the position of Chief Scientific Officer & Research President at Pfizer Inc. Dr. Dolsten is also on the board of New York Academy of Sciences, Karyopharm Therapeutics, Inc. and PhRMA Foundation and Member of Royal Swedish Academy of Engineering Sciences and Member of Government-University-Industry Research Roundtable. In the past he occupied the position of Principal at OrbiMed Advisors LLC and Partner at OrbiMed Advisors Private Equity (a subsidiary of OrbiMed Advisors LLC), President for Wyeth Research, EVP, Global Head-Pharma Research & Discovery at Boehringer Ingelheim Pharmaceuticals, Inc., Senior Vice President for Wyeth Corp. and Member-Benefits, Law & Regulatory Committee at Wyeth Pharmaceuticals LLC. Dr. Dolsten received a doctorate from the University of Lund.

View full profile